// September 17, 2020
Glycosylation in monoclonal antibody treatments for COVID-19...
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
Biologics
// March 16, 2021
Quality Raw Materials & Collaboration Essential to mAb COVID-19 Treatment Access in L...
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
// January 07, 2021
Ensuring quality COVID-19 vaccine delivery through the ‘last mile’...
The COVID-19 pandemic has presented unprecedented challenges around the world, including to national public health systems and the international biopharmaceutical industry.
// July 30, 2020
The Role of Standards in Supporting Quality Vaccines Manufacturing and Distribution...
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.
// July 07, 2020
USP Convenes Global Biologics Summit to Identify Challenges to Quality Biologics Medi...
U.S. Pharmacopeia (USP) brought together preeminent thought leaders from industry, global health organizations, regulatory agencies, standards setting organizations and other stakeholders at its virtual Global Biologics Summit on June 11, 2020.
// February 04, 2020
Strengthening Biotherapeutic Innovations through Emerging Analytical Tools...
Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.
// December 10, 2019
Antibiotics manufacturing components can trigger adverse reactions. Standards help re...
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?
// November 20, 2019
A new generation of tools and standards for biologic medicine quality...
Patients, their families and health care providers alike care about the quality of their medicines. For nearly 200 years, USP has contributed to the quality of medicines by providing publicly-available standards.
// August 16, 2018
The Role of Standards in Personalized Medicine
As personalized therapies have become a reality rather than a distant promise, the tools needed to ensure the quality of these medicines grow increasingly important.
Show 11 More